146 related articles for article (PubMed ID: 16363556)
1. [Recent topics on important drugs for H. pylori eradication: Omeprazole].
Kataoka H; Jho T; Itoh M
Nihon Rinsho; 2005 Nov; 63 Suppl 11():333-7. PubMed ID: 16363556
[No Abstract] [Full Text] [Related]
2. [Recent topics on important drugs for H. pylori eradication: Rabeprazole].
Sugimoto M; Furuta T; Nakmura A; Shirai N
Nihon Rinsho; 2005 Nov; 63 Suppl 11():350-3. PubMed ID: 16363558
[No Abstract] [Full Text] [Related]
3. [Cytochrome P450 2C19 genotype -based second line therapy with amoxicillin and lansoprazole after failure of initial helicobacter pylori eradication therapy].
Asano M; Taniwaki H; Tsuji D; Sato Y; Shimizu T
Nihon Rinsho; 2005 Dec; 63 Suppl 12():450-3. PubMed ID: 16416832
[No Abstract] [Full Text] [Related]
4. [Investigation about 3rd line eradication of H. pylori].
Nakagawa S; Kato M; Shimizu Y; Nakagawa M; Asaka M
Nihon Rinsho; 2005 Nov; 63 Suppl 11():466-9. PubMed ID: 16363580
[No Abstract] [Full Text] [Related]
5. [Influence of cytochrome P450 2C19 genetic polymorphism on H. pylori eradication therapy].
Hikichi T; Irisawa A; Abe C; Obara K; Sato Y
Nihon Rinsho; 2005 Nov; 63 Suppl 11():569-72. PubMed ID: 16363603
[No Abstract] [Full Text] [Related]
6. Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient.
Furuta T; Takashima M; Shirai N; Xiao F; Hanai H; Ohashi K; Ishizaki T
Clin Pharmacol Ther; 2000 Jun; 67(6):684-9. PubMed ID: 10872651
[TBL] [Abstract][Full Text] [Related]
7. [High dose dual PPI/AMPC therapy for the treatment of Helicobacter pylori infection after failure of usual standard triple PPI/AMPC/CAM therapy].
Shirai N; Furuta T; Sugimoto M; Nakamura A
Nihon Rinsho; 2005 Nov; 63 Suppl 11():438-41. PubMed ID: 16363575
[No Abstract] [Full Text] [Related]
8. [High dose dual PPI/AMPC therapy for the treatment of Helicobacter pylori infection after failure of usual standard triple PPI/AMPC/CAM therapy: CYP2C19 polymorphism].
Shirai N; Furuta T
Nihon Rinsho; 2002 Feb; 60 Suppl 2():439-44. PubMed ID: 11979823
[No Abstract] [Full Text] [Related]
9. Determinants of non-response in Helicobacter pylori eradication trials.
Klotz U; Treiber G; Schwab M
J Gastroenterol Hepatol; 2005 Sep; 20(9):1471. PubMed ID: 16105147
[No Abstract] [Full Text] [Related]
10. Helicobacter pylori eradication, CYP2C19 and omeprazole doses.
Manes G
Aliment Pharmacol Ther; 2005 Aug; 22(3):273-4; author reply 274. PubMed ID: 16091066
[No Abstract] [Full Text] [Related]
11. CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori.
Tanigawara Y; Aoyama N; Kita T; Shirakawa K; Komada F; Kasuga M; Okumura K
Clin Pharmacol Ther; 1999 Nov; 66(5):528-34. PubMed ID: 10579481
[TBL] [Abstract][Full Text] [Related]
12. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
Furuta T; Shirai N; Takashima M; Xiao F; Hanai H; Sugimura H; Ohashi K; Ishizaki T; Kaneko E
Clin Pharmacol Ther; 2001 Mar; 69(3):158-68. PubMed ID: 11240980
[TBL] [Abstract][Full Text] [Related]
13. [A strategy for second-line anti-Helicobacter pylori therapy in patients with previously failed treatment].
Ohkusa T; Watanabe M
Nihon Rinsho; 2001 Feb; 59(2):323-7. PubMed ID: 11218406
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection.
Take S; Mizuno M; Ishiki K; Nagahara Y; Yoshida T; Inaba T; Yamamoto K; Okada H; Yokota K; Oguma K; Shiratori Y
Am J Gastroenterol; 2003 Nov; 98(11):2403-8. PubMed ID: 14638340
[TBL] [Abstract][Full Text] [Related]
15. Polymorphisms and the pocketbook: the cost-effectiveness of cytochrome P450 2C19 genotyping in the eradication of Helicobacter pylori infection associated with duodenal ulcer.
Lehmann DF; Medicis JJ; Franklin PD
J Clin Pharmacol; 2003 Dec; 43(12):1316-23. PubMed ID: 14615467
[TBL] [Abstract][Full Text] [Related]
16. [Susceptibility to antibiotics and drug metabolism in patients with H. pylori infection refractory to the initial treatment--therapeutic strategy based on susceptibility to CAM and CYP2C19 polymorphism].
Furuta T; Sugimoto M; Nakamura A; Shirai N
Nihon Rinsho; 2005 Nov; 63 Suppl 11():426-33. PubMed ID: 16363573
[No Abstract] [Full Text] [Related]
17. [Recent topics on important drugs for H. pylori eradication: Pantoprazole sodium].
Okazaki K; Mori S; Tahashi K
Nihon Rinsho; 2005 Nov; 63 Suppl 11():354-60. PubMed ID: 16363559
[No Abstract] [Full Text] [Related]
18. Pharmacogenomics of proton pump inhibitors.
Furuta T; Shirai N; Sugimoto M; Ohashi K; Ishizaki T
Pharmacogenomics; 2004 Mar; 5(2):181-202. PubMed ID: 15016609
[TBL] [Abstract][Full Text] [Related]
19. Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism.
Sheu BS; Kao AW; Cheng HC; Hunag SF; Chen TW; Lu CC; Wu JJ
Aliment Pharmacol Ther; 2005 Feb; 21(3):283-8. PubMed ID: 15691303
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism.
Chen MC; Hu CT; Wang LY; Lin HH
Aliment Pharmacol Ther; 2005 Aug; 22(3):274-5; author reply 275-6. PubMed ID: 16091067
[No Abstract] [Full Text] [Related]
[Next] [New Search]
